Literature DB >> 28905140

Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease.

Marie-Thérèse Abi-Wardé1, Célina Roda1, Jean-Baptiste Arnoux1, Aude Servais1,2, Florence Habarou1,3, Anais Brassier1, Clément Pontoizeau3, Valérie Barbier1, Manuella Bayart1, Virginie Leboeuf1, Bernadette Chadefaux-Vekemans1,3, Sandrine Dubois1, Murielle Assoun1, Claire Belloche1, Jean-Meidi Alili4, Marie-Caroline Husson4, Fabrice Lesage1,5, Laurent Dupic1,5, Benoit Theuil6, Chris Ottolenghi1,3, Pascale de Lonlay7.   

Abstract

BACKGROUND: Maple syrup urine disease (MSUD) is a rare disease that requires a protein-restricted diet for successful management. Little is known, however, about the psychosocial outcome of MSUD patients. This study investigates the relationship between metabolic and clinical parameters and psychosocial outcomes in a cohort of patients with neonatal-onset MSUD.
METHODS: Data on academic achievement, psychological care, family involvement, and biochemical parameters were collected from the medical records of neonatal MSUD patients treated at Necker Hospital (Paris) between 1964 and 2013.
RESULTS: Thirty-five MSUD patients with a mean age of 16.3 (2.1-49.0) years participated. Metabolic decompensations (plasma leucine >380 μmol/L) were more frequent during the first year of life and after 15 years, mainly due to infection and dietary noncompliance, respectively. Leucine levels increased significantly in adulthood: 61.5% of adults were independent and achieved adequate social and professional integration; 56% needed occasional or sustained psychological or psychiatric care (8/19, with externalizing, mood, emotional, and anxiety disorders being the most common). Patients needing psychiatric care were significantly older [mean and standard deviation (SD) 22.6 (7.7) years] than patients needing only psychological follow-up [mean (SD) 14.3 (8.9) years]. Patients with psychological follow-up experienced the highest lifetime number of decompensations; 45% of families had difficulty coping with the chronic disease. Parental involvement was negatively associated with the number of lifetime decompensations.
CONCLUSION: Adults had increased levels of plasma leucine, consistent with greater chronic toxicity. Psychological care was associated with age and number of decompensations. In addition, parental involvement appeared to be crucial in the management of MSUD patients.

Entities:  

Keywords:  Decompensation; Leucine; MSUD; Maple syrup urine disease; Psychosocial outcome

Mesh:

Substances:

Year:  2017        PMID: 28905140     DOI: 10.1007/s10545-017-0083-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  Exposure to leucine alters glutamate levels and leads to memory and social impairment in zebrafish.

Authors:  Isabela da Silva Lemos; Leticia Burato Wessler; Mariane Bernardo Duarte; Guilherme Lodetti da Silva; Henrique Teza Bernardo; Gabriela Candiotto; Carolina Antunes Torres; Fabricia Petronilho; Eduardo Pacheco Rico; Emilio Luiz Streck
Journal:  Metab Brain Dis       Date:  2022-08-30       Impact factor: 3.655

2.  Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice.

Authors:  Clément Pontoizeau; Marcelo Simon-Sola; Clovis Gaborit; Vincent Nguyen; Irina Rotaru; Nolan Tual; Pasqualina Colella; Muriel Girard; Maria-Grazia Biferi; Jean-Baptiste Arnoux; Agnès Rötig; Chris Ottolenghi; Pascale de Lonlay; Federico Mingozzi; Marina Cavazzana; Manuel Schiff
Journal:  Nat Commun       Date:  2022-06-07       Impact factor: 17.694

3.  Intravenous administration of a branched-chain amino-acid-free solution in children and adults with acute decompensation of maple syrup urine disease: a prospective multicentre observational study.

Authors:  Jean-Meidi Alili; Marie-Pierre Berleur; Marie-Caroline Husson; Karine Mention; Manuel Schiff; Jean-Baptiste Arnoux; Anaïs Brassier; Anne-Sophie Guemman; Coraline Grisel; Sandrine Dubois; Marie-Thérèse Abi-Wardé; Christine Broissand; Aude Servais; Myriam Dao; Pascale de Lonlay
Journal:  Orphanet J Rare Dis       Date:  2022-05-16       Impact factor: 4.303

4.  Predictors of acute metabolic decompensation in children with maple syrup urine disease at the emergency department.

Authors:  Yılmaz Yıldız; Leman Akcan Yıldız; Ali Dursun; Ayşegül Tokatlı; Turgay Coşkun; Özlem Tekşam; Hatice Serap Sivri
Journal:  Eur J Pediatr       Date:  2020-02-11       Impact factor: 3.183

5.  Evaluation of plasma biomarkers of inflammation in patients with maple syrup urine disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuck; Gustavo C Ferreira; João Quevedo; João Seda Neto; Tatiana Amorim; Jose S Camelo; Ana Vitoria Barban Margutti; Rafael Hencke Tresbach; Fernanda Sperb-Ludwig; Raquel Boy; Paula F V de Medeiros; Ida Vanessa D Schwartz; Emilio Luiz Streck
Journal:  J Inherit Metab Dis       Date:  2018-05-08       Impact factor: 4.982

6.  Real-world management of maple syrup urine disease (MSUD) metabolic decompensations with branched chain amino acid-free formulas in France and Germany: A retrospective observational study.

Authors:  Pascale de Lonlay; Roland Posset; Ulrike Mütze; Karine Mention; Delphine Lamireau; Manuel Schiff; Aude Servais; Jean Baptiste Arnoux; Anaïs Brassier; Myriam Dao; Claire Douillard; Chris Ottolenghi; Clément Pontoizeau; Federica Miotto; Jeannie Le Mouhaër
Journal:  JIMD Rep       Date:  2021-03-06

7.  Natural history of children and adults with maple syrup urine disease in the NBS-MSUD Connect registry.

Authors:  Aileen Kenneson; Yetsa Osara; Theresa Pringle; Lauren Youngborg; Rani H Singh
Journal:  Mol Genet Metab Rep       Date:  2018-01-28

8.  Pre-school neurocognitive and functional outcomes after liver transplant in children with early onset urea cycle disorders, maple syrup urine disease, and propionic acidemia: An inception cohort matched-comparison study.

Authors:  Shailly Jain-Ghai; Ari R Joffe; Gwen Y Bond; Komudi Siriwardena; Alicia Chan; Jason Y K Yap; Morteza Hajihosseini; Irina A Dinu; Bryan V Acton; Charlene M T Robertson
Journal:  JIMD Rep       Date:  2020-01-27

9.  Intravenous branched-chain amino-acid-free solution for the treatment of metabolic decompensation episodes in Spanish pediatric patients with maple syrup urine disease.

Authors:  Paula Sánchez-Pintos; Silvia Meavilla; María Goretti López-Ramos; Ángeles García-Cazorla; Maria L Couce
Journal:  Front Pediatr       Date:  2022-08-15       Impact factor: 3.569

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.